- Home
- NCPL vs MTNB Comparison
NCPL vs MTNB Comparison
Compare NCPL & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | MTNB |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NCPL | MTNB |
|---|---|---|
| Price | $1.09 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.1M | 313.9K |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,750.00 |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $0.48 |
| 52 Week High | $8.75 | $3.09 |
Technical Indicators
Market Signals| Indicator | NCPL | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 72.68 |
| Support Level | $0.47 | $0.55 |
| Resistance Level | $2.62 | $0.98 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 47.47 | 85.44 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.